|
[1]WANG YY, NIE QH.Current status of research on direct-acting antiviral agents and their application in treatment of chronic hepatitis C[J].Chin Hepatol, 2016, 21 (2) :140-142. (in Chinese) 王媛媛, 聂青和.直接抗病毒药物研究及其治疗慢性丙型肝炎现状[J].肝脏, 2016, 21 (2) :140-142.
|
|
[2]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
|
[3]WHO Guidelines Approved by the Guidelines Review Committee.In:Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[Z].Geneva:World Health Organization.Copyright (c) World Health Organization2016.
|
|
[4]PANEL AIHG.Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|
|
[5]LAWITZ E, MATUSOW G, DEJESUS E, et al.Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis:a phase 3 study (OPTIMIST-2) [J].Hepatology, 2016, 64 (2) :360-369.
|
|
[6]KWO P, GITLIN N, NAHASS R, et al.Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis:OPTIMIST-1, a phase 3, randomized study[J].Hepatology, 2016, 64 (2) :370-380.
|
|
[7]LAWITZ E, SULKOWSKI MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.
|
|
[8]ABERGEL A, METIVIER S, SAMUEL D, et al.Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection[J].Hepatology, 2016, 64 (4) :1049-1056.
|
|
[9]ABERGEL A, ASSELAH T, METIVIER S, et al.Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection:an open-label, multicentre, single-arm, phase 2 study[J].Lancet Infect Dis, 2016, 16 (4) :459-464.
|
|
[10]KOHLI A, KAPOOR R, SIMS Z, et al.Ledipasvir and sofosbuvir for hepatitis C genotype 4:a proof-of-concept, single-centre, open-label phase 2a cohort study[J].Lancet Infect Dis, 2015, 15 (9) :1049-1054.
|
|
[11]GANE EJ, HYLAND RH, AN D, et al.Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection[J].Gastroenterology, 2015, 149 (6) :1454-1461.
|
|
[12]BOURLIERE M, BRONOWICKI JP, de LEDINGHEN V, et al.Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy:a randomised, doubleblind, phase 2 trial (SIRIUS) [J].Lancet Infect Dis, 2015, 15 (4) :397-404.
|
|
[13]LAWITZ E, POORDAD FF, PANG PS, et al.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR) :an open-label, randomised, phase 2 trial[J].Lancet, 2014, 383 (9916) :515-523.
|
|
[14]KOWDLEY KV, GORDON SC, REDDY KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].New Engl J Med, 2014, 370 (20) :1879-1888.
|
|
[15]AFDHAL N, ZEUZEM S, KWO P, et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].New Engl J Med, 2014, 370 (20) :1889-1898.
|
|
[16]AFDHAL N, REDDY KR, NELSON DR, et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].New Engl J Med, 2014, 370 (16) :1483-1493.
|
|
[17]LAWITZ E, MAKARA M, AKARCA US, et al.Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis[J].Gastroenterology, 2015, 149 (4) :971-980.
|
|
[18]HEZODE C, ASSELAH T, REDDY KR, et al.Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I) :a randomised, open-label trial[J].Lancet, 2015, 385 (9986) :2502-2509.
|
|
[19]FELD JJ, MORENO C, TRINH R, et al.Sustained virologic response of 100%in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks[J].J Hepatol, 2016, 64 (2) :301-307.
|
|
[20]FERENCI P, BERNSTEIN D, LALEZARI J, et al.ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV[J].New Engl J Med, 2014, 370 (21) :1983-1992.
|
|
[21]ANDREONE P, COLOMBO MG, ENEJOSA JV, et al.ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97%and 100%sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection[J].Gastroenterology, 2014, 147 (2) :359-365.
|
|
[22]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.
|
|
[23]SULKOWSKI MS, GARDINER DF, RODRIGUEZ-TORRES M, et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].New Engl J Med, 2014, 370 (3) :211-221.
|
|
[24]SULKOWSKI M, HEZODE C, GERSTOFT J, et al.Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY) :a randomised, open-label phase 2 trial[J].Lancet, 2015, 385 (9973) :1087-1097.
|
|
[25]LAWITZ E, GANE E, PEARLMAN B, et al.Efficacy and safety of 12weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (CWORTHY) :a randomised, open-label phase 2 trial[J].Lancet, 2015, 385 (9973) :1075-1086.
|
|
[26]FOSTER GR, AFDHAL N, ROBERTS SK, et al.Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection[J].New Engl J Med, 2015, 373 (27) :2608-2617.
|
|
[27]FELD JJ, JACOBSON IM, HZODE C, et al.Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection[J].New Engl J Med, 2015, 373 (27) :2599-2607.
|
|
[28]CURRY MP, O'LEARY JG, BZOWEJ N, et al.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis[J].New Engl J Med, 2015, 373 (27) :2618-2628.
|
|
[29]DICK TB, LINDBERG LS, RAMIREZ DD, et al.A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection[J].Hepatology, 2016, 63 (2) :634-643.
|
|
[30]HERNANDEZ MD, SHERMAN KE.HIV/hepatitis C coinfection natural history and disease progression[J].Curr Opin HIV AIDS, 2011, 6 (6) :478-482.
|
|
[31]KHATRI A, DUTTA S, DUNBAR M, et al.Evaluation of drug-drug interactions between direct-acting anti-hepatitis C virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine[J].Antimicrob Agents Ch, 2016, 60 (5) :2965-2971.
|
|
[32]POIZOT-MARTIN I, NAQVI A, OBRY-ROGUET V, et al.Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients[J].PLo S One, 2015, 10 (10) :e141164.
|
|
[33]BADRI PS, DUTTA S, WANG H, et al.Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir[J].Antimicrob Agents Ch, 2016, 60 (1) :105-114.
|
|
[34]RENET S, CHAUMAIS M, ANTONINI T, et al.Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone:2 cases including a rechallenge[J].Gastroenterology, 2015, 149 (6) :1378-1380.
|
|
[35]WYLES DL, RUANE PJ, SULKOWSKI MS, et al.Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1[J].New Engl J Med, 2015, 373 (8) :714-725.
|
|
[36]POCKROS PJ, REDDY KR, MANTRY PS, et al.Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J].Gastroenterology, 2016, 150 (7) :1590-1598.
|
|
[37]ROTH D, NELSON DR, BRUCHFELD A, et al.Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) :a combination phase 3study[J].Lancet, 2015, 386 (10003) :1537-1545.
|
|
[38]SORIANO V, LABARGA P, de MENDOZA C, et al.New hepatitis C therapies for special patient populations[J].Expert Opin Pharmaco, 2016, 17 (2) :217-229.
|
|
[39]UEDA Y, UEMOTO S.Interferon-free therapy for hepatitis C in liver transplant recipients[J].Transplantation, 2016, 100 (1) :54-60.
|
|
[40]SURAWEERA D, SAAB EG, TONG MJ, et al.Timing of hepatitis C antiviral therapy in liver transplant recipients with direct-acting agents[J].Exp Clin Transplant, 2016, 14 (3) :243-251.
|
|
[41]ENDE AR, KIM NH, YEH MM, et al.Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir:a case report[J].J Med Case Rep, 2015, 9 (1) :164.
|
|
[42]COLLINS JM, RAPHAEL KL, TERRY C, et al.Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir[J].Clin Infect Dis, 2015, 61 (8) :1304-1306.
|
|
[43]GANE EJ, SCHWABE C, HYLAND RH, et al.Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections[J].Gastroenterology, 2016, 151 (3) :448-456.
|
|
[44]GANE EJ, KOWDLEY KV, POUND D, et al.Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype2, 3, 4, or 6 infections in an open-label, phase 2 trial[J].Gastroenterology, 2016, 151 (5) :902-909.
|
|
[45]ZHU T, NIE QH.New progress in development of animal models of hepatitis C virus infection[J].J Clin Hepatol, 2015, 31 (1) :123-126. (in Chinese) 朱婷, 聂青和.HCV感染动物模型的研究进展[J].临床肝胆病杂志, 2015, 31 (1) :123-126.
|
|
[46]WANG M, NIE QH.Current status of Chinese herbal medicine and active extracts in treatment of hepatitis C[J].Chin Hepatol, 2014, 19 (2) :140-143. (in Chinese) 汪萌, 聂青和.中草药及有效提取物治疗丙型肝炎的现状[J].肝脏, 2014, 19 (2) :140-143.
|
DownLoad: